CXCR4 mutation subtypes impact response and survival outcomes in ibrutinib-treated WM

Key Findings

• ●CXCR4 nonsense mutations associated with more aggressive presentation
• ●Lower major response rates (67% vs 86%) in CXCR4-mutated patients on ibrutinib
• ●CXCR4 mutations and low platelets predict worse PFS

Referenced in (1 disease)